Clinuvel Pharmaceuticals Limited
As of Oct 22, 2026, Clinuvel Pharmaceuticals is in Stage 4, the downtrend phase, now in week 7 (since Sep 10, 2026). It closed at $5.03, 42.2% below its 52-week high and below its 200-day average, which is falling.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland,… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CUVL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CUVL among Biotechnology295th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …295 | CUVL | Stage 4 · wk 7 | 31 | −13.1% |
Clinuvel Pharmaceuticals: quick answers
What stage is Clinuvel Pharmaceuticals in?
As of Oct 22, 2026, Clinuvel Pharmaceuticals (CUVL) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Clinuvel Pharmaceuticals in an uptrend?
No. Clinuvel Pharmaceuticals is in a Stage 4 downtrend. It trades 26.6% below its 200-day average, which is falling.
How far is Clinuvel Pharmaceuticals from its 52-week high?
Clinuvel Pharmaceuticals closed at $5.03 on Oct 22, 2026, 42.2% below its 52-week high of $8.70. Its 52-week low is $5.03.
How has Clinuvel Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Clinuvel Pharmaceuticals is down 34.1% over the past year and down 37.7% so far in 2026.
Which sector and industry is Clinuvel Pharmaceuticals in?
Clinuvel Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.